Peptide therapy for anti-aging: what TikTok gets wrong

What did @youngeryoudoc actually say?

@youngeryoudoc called GHK-Cu a "Wolverine anti-aging peptide" with an ambitious list of effects: reduced wrinkles, increased collagen, hair growth, DNA repair, nerve regeneration, cancer prevention, anti-inflammation, and wound healing. They also made a point that most people will appreciate: you can use it topically, not just via injection. The framing is enthusiastic, the list is long, and the word "prevents cancer" slipped in there fast enough that most viewers probably didn't blink.

That last claim is the one that should make you pump the brakes. The rest of the video is grounded in real, published science, even if it's presented in the breathless tone of someone who just discovered something they want tattooed on their arm. Let's go through it.

Does the science back this up?

Mostly, yes, with one significant exception. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a legitimate area of research with a decades-long paper trail. The skin claims have the strongest backing. The cancer claim does not.

The foundational work here comes from Loren Pickart, who identified GHK-Cu in human plasma in the 1970s and has published extensively on it since. A 2015 review by Pickart and Margolina in Cosmetics summarized gene expression data showing GHK-Cu upregulates genes involved in collagen synthesis, anti-inflammatory pathways, and antioxidant defense. Wound healing effects have been demonstrated in animal models. The gene expression angle is real: a 2012 study by Pickart et al. in Journal of Aging Research analyzed Broad Institute data and found GHK-related gene sets overlapping with pathways linked to DNA repair and cellular maintenance. That's the basis for the "changes how genes are expressed" claim, and it's a fair summary of the data, with caveats.

The nerve regeneration claim has some preclinical support. Kang et al. (2009) in Archives of Pharmacal Research found GHK-Cu promoted neurite outgrowth in cell culture. Human data is sparse.

What did they get wrong (or right)?

The phrase "prevents cancer" is the problem. The actual research, primarily from Pickart's gene expression analyses, suggests GHK-Cu may downregulate genes associated with cancer progression and upregulate tumor suppressor pathways. That is not the same as preventing cancer. It's a mechanistic hypothesis derived from gene array data, not a clinical outcome. No randomized controlled trial has shown GHK-Cu prevents cancer in humans. Stating it flatly as a benefit is irresponsible, even if the underlying biology is interesting.

On the other hand, the creator deserves credit for getting the biology of decline right. GHK-Cu plasma levels do drop significantly with age, from roughly 200 ng/mL in young adults to around 80 ng/mL by age 60, per Pickart's earlier work. The observation that topical application is a viable delivery route is also accurate: GHK-Cu has good skin penetration compared to many peptides, which is why it appears in commercial cosmeceuticals. Calling it "naturally occurring" is accurate. The gene expression framing, though simplified, reflects real published science.

What should you actually know?

GHK-Cu is one of the better-studied peptides in the cosmeceutical space, which still means the human trial data is thin. Most of the impressive-sounding mechanisms come from in vitro studies, animal models, or gene expression analyses, not phase III clinical trials in humans. That gap matters.

Topical GHK-Cu is available in cosmetic formulations without a prescription. The concentration matters, and most over-the-counter products contain far less than what's used in research settings. Compounded injectable GHK-Cu exists but is a different conversation entirely, with different regulatory and safety considerations. Those are not interchangeable.

If you're interested in GHK-Cu for skin or wound-related applications, there's enough legitimate science to have a real conversation with a clinician. If someone is selling it to you as a cancer preventive, walk away. The data doesn't support that claim, and nobody reputable is making it in a clinical context.